UCB Holds Breath Amid Concerns Of Second FDA Rejection Of Bimzelx
Agency Has Questions After Inspection
The US Food and Drug Administration has published a report after an inspection of UCB’s Belgian facility where Bimzelx is manufactured and the findings suggest that a long-awaited approval for the psoriasis drug should not be taken for granted.
